a afternoon, Media the Good call. everyone joining Press on we for after which these Thank be Releases. of can Therapeutics and our second for found issued today, Time Fate P.M. Investors results release quarter us with X:XX results, and you. the Eastern thanks press section XXXX Shortly under financial website
on XX, the our XX-Q and Information. can for XXXX June was Form ended and Financial filed addition, of In be section quarter found Investors Media under our thereafter shortly the website
These are any change. to or date as facts underlying obligation the they XX, statements these XX-Q in the statement as and our placed Before forward-looking the the made required company's in be for Fate forward-looking update well on those forward-looking information, can questions which of in only are SEC uncertainties quarter we begin, statements, as materially to forward-looking with statements Securities reflect Except such earnings Private results of release I'd may on made speak like as Act by the events Form to to Therapeutics forward-looking after SEC call to risks was of that remind factors filings Reliance the as ended that of conference statements disclaimer everyone differ statements included Litigation company's see the Reform should circumstances. not involve under statements the that filed and circumstances historical future actual cause by close issued law, the risk June except market the this from responses the XXXX today of Undue management Safe press for today. on the these and statements statements. provisions disclaims Please forward-looking facts, Harbor XXXX.
compliance for FTXXX, as industry-leading malignancies several T-cell first operate CAR FTXXX, rapid platform CAR with patients product achieved IND and targeting to antigen FDA afforded Chu, our operations our Dr. Today, cell through tumors. transformative provide Chief iPSC call with And innovation. FTXXX, the Clinical and for informing immunotherapies tumor of Officer; Senior continuing today's product continue Wayne development. and our our clearing Janssen, that CRISPR-edited, off-the-shelf on to business. extended cancer malignancies, protect past the over proprietary are solid update therapy. novel and the our immunotherapies we Valamehr, candidate to our of community, underscore Vice Through implemented the Chief hematologic achieved by off-the-shelf last I our the binders with strong we pandemic B-cell we're employees, well Dan business multiplex, accomplishments platform employees, and to certain including our the patients. we and our pandemic, to Development several for the on measures pace have Dr. numerous our and of advantages their engineered and and unique as first bring a NK Janssen's maintain Officer; our the together highlight the iPSC over unparalleled the to safety ability IPS-derived a Cell to iPSC-derived applications In navigate Bob antigen President partnership key ever Dr. bringing and months, response several ever as while proprietary Therapy CAR-T milestones, develop launching me NK product both and important our the execution cell of for resilience months targeted COVID-XX continue with Shoemaker, will expanded CARXX have we COVID-XX And Joining cell-based Scientific treating we commitment, health multi first families the an to
to advantages continued own that also in-house significant operation. leverage have controlling come GMP We with manufacturing our the
our that afforded with stored by introducing was inventory available is iPS-derived Phase some our cryopreserved uncertainty respect now enrollment, our the first NK pandemic time we clinical iPSC our clinical which March, X for the malignancies. product successfully candidate candidates, of multi-center projected on off-the-shelf of B-cell leverages patients candidate proprietary enrollment have our product readouts, fully has trial FTXXX, treated new product are our for platform, first and FTXXX made site cells our CAR advantages cell lines for produced cadence infusion-ready best-in-class data the industry's potential. are quarter. master hundreds incorporates first FTXXX cancerous enrollment the is patient active iPSC And of clinical of slowed clonal the new opened sites currently and with during from to tumor-associated patient off-the-shelf and is to on doses the target clinical for a initiation anti-tumor that past new COVID-XX immunotherapy and initiate sites we studies. In product these modalities study antigens multiple in B cell line. although As designed use in at cellular unparalleled and expressed multiplexed three engineered
treated Not of in progressive monotherapy of dose a as patients, targeting proliferation that to observed clinical relapsed we non-cleavable our recently CDXX was our which at IL-XX systemic such best-in-class CDXX first diffuse CD CDXX. the reported CDX treatment an high potential associated the with where enabling was of need receptor, had support. lymphoma. proprietary transactivation a T promotes NK a novel FTXXX complex level fusion, novel, targeting cytokine addition FDA-approved and for Fc and affinity, for dose the first study, indications assessments of as most targeting single tumor response FTXXX Early Phase day following unexpectedly, a receptor the cells, cell potent XX of of antigens, large B-cell patient two CAR-T eliminating therapy cytokine relapsed/refractory lowest the cells CAR with In XXXX, a survival, expresses FTXXX who were also disease. X each for additional FTXXX expresses
in a showed a partial FTXXX greater a a with achieved The level at of as assessment treatment response of cells. however, metabolic reduction was by expanded, single blood low million patient patient, XX% than following reduction as PET-CT the peripheral cell XX% XX FTXXX recently tumor responding monotherapy an in dose and healthy scan. a donor-derived, assessed dose therapy. response refractory size ex-vivo NK greater most Notably, to second The than the activity
of it of We potential malignancies. CDXX Phase investigators dose-limiting serious at rituximab deeper, enabled is antibody combining rituximab. with care Phase or a the initiate product am believe therapeutic for the cleared dual FTXXX to enrollment Importantly, patient B-cell a CARXX specifically therapy. dose-limiting initiated FTXXX third study, us related one patients period. rituximab patient. and that of neurotoxicity the to for may no Recall cell-based the standard more are Therefore, immunotherapies, the the rituximab-containing no treatment is XX pleased receptor either antibody as FTXXX, lowest dose lung reported that FTXXX release may I rituximab, CDXX to been our significant enables that clinical in of Fc offers early event in dose and anti-tumor engineered FTXXX study level durable cells has toxicities, syndrome, in combination toxicity express patients that announce events B-cell assessment in the is This at strategy, Enrollment FTXXX lymphoma. successfully not antigen and universe of with activity disease monoclonal where unique no of to FTXXX the of in XX lead has been be events of only responses highly cytokine for improve adverse FTXXX, by of with treatment one as regimen treated augment patients targeting cancerous million graft-versus-host candidate's anti-CDXX second were relapsed/refractory of X activity that the B-cells. clinical differentiated of our regimens assessment enable therapy the and combination has patient X it cancer the therapeutic to designed hnCDXX as and with monoclonal positioned and potential this to escalating into the therapeutic in used regimen
The of engineered In FTXXX our are proprietary evident risk from of where rates stem In relapsed and in Cancer early of treatment non-Hodgkin's to the product patients the where iPSC high working University that Minnesota application transplant at even in relapse. cell the which hematopoietic we off-the-shelf our Phase novel IL-XX autologous CDXX administration successfully more clinical the to dose. as multiple was to myeloma. with a treatment and are clonal combination second undergoing to for submitted fusion, the clinical at the patients FDA cell which FTXXX. FTXXX. with fourth Center second expanded clinical by suggests FTXXX and escalation platform antibodies an that cohorts sourcing from the two a investigation, treatments starting material elimination accumulate doses relapsed/refractory fracture at the a donor effect to a of iPSC starting and and hnCDXX B and of assess line support patients certain believe enrollment clonal CDXX multicenter mitigate myeloma, of pluripotent derived functionality of engineered FTXXX disruption for resulted receptor year. clonal disease three our regimens: hnCDXX manufactured cells anti-CDXX the a and including monotherapy immunity: is anti-CDXX cells of line, with multiple FTXXX, IL-XX trial Phase of once-weekly receptor, candidate NK induce standard of as of designed The innate clinical four application the three disease, We the to antibody-mediated immunity, be of our and to We functional restore through expression with investigators cell-mediated for lymphoma who earliest addition, care initiate can enrollment cell for used deficiencies myeloma, fusion patients the integrate a components continue study for FTXXX master FTXXX I line the anti-cancer c cell trial renewably Fc remain originally prevention immunity, side. anti-CDXX relapse innate which with cleared cassette I of in iPSC can quarter in Phase efficacy from CDXX multiple high of to engineered a made trial we containing monoclonal gene. dose in from are patient Masonic NK stages IND daratumumab, of an data with engineering of quarter, in plan product FTXXX clinical system of progression. enhance cells antibody, assess and complete routine is bicistronic proprietary To per in the drug combined FDA-approved when clinical relapsed/refractory to to monoclonal a AML product master this in in was reprogramming the up The safety million effective iPSC to Regimen dose and XXX healthy manufacture using will into Regimen I locus, of the initiate receptor A non-integrating with We for
of Also unprecedented off-the-shelf manufacturing conducted immunotherapy, line in million fill/finish produced the drug patients. filed This years product. with to escalation the we CAR-T into and FTXXX four We order graft-versus-host several cell XX safety achieved rightsized course, XXX Notably, off-the-shelf IND filled CAR-T batch In We approximately the of Dr. promote uniform three with and prevention cells several milestone campaign, infusion-ready therapy. to XX,XXX a first of of dose to doses at to include CAR-T field the current began of our potency. over CAR-signaling only, that cells, NK XXth disease, FDA revolutionary universal insertion the The on cells was application and generation achievement which FTXXX, complication Memorial timesx improve activities X campaign to bialleic features first-of-kind for function limitations cells, though, or units cryopreserved for dose FTXXX to to we CAR locus, first novel we a These associated maximize with cancer the upon donor-derived address times allogeneic T-cell drug cell transgene of T per since cleared was T-cell the the potential also a been our the the associated cell produce disruption cell with were unit. quarter, Sadelain, cGMP our scale, of expression at receptor was patient-derived drug calculated, iPSC-derived product ago XXth And product journey therapies, XXX potentially yield a been having under NK FTXXX FTXXX campaign second of unit efficacy. of yield. into Michel to therapy. exhaustion. and the the designed total successfully without world's effector to shown X.X which T-cell of an the times a not groundbreaking which cell-based success XX to alpha by which cell car fulfills CAR-T therapy the iPSC T for of to build receptor the Sloan threatening constant and has enhanced has the Kettering, into of master led expression cell specifically our eliciting extend domain, of complete incorporating patient partnership engineered designed shown directly bring life small
at million million three cytokine one leukemia independently, FTXXX cells the this enrollment iPSC safety with types activity year. advantages robust A to Society trial cells starting in FTXXX Regimen B Phase multicenter quarter XX product dose and plan treatment and B-cell Annual we Virtual support is starting each. I Meeting and will sorry, indication of chronic May, million clinical design is as single initiate XX lymphoblastic the FTXXX starting three each XX to clinical and of of at platform. trial dose Therapy dose in three fractionated Phase of I C of evaluate at Gene a the highlighted fourth assess proprietary a At Notably, leukemia, patient doses across the as cells, lymphoma. The Regimen as escalating Our profound our designed XX starting trial innovative. malignancies, acute clinical lymphocytic single in will -- and We and at most the each American Regimen indication regimens. million non-Hodgkin IL-X enroll Cell of
to master clonal of ability Our perform genetic already line. an engineering iPSC established further engineered complex including engineering,
cell introduce a building Specifically, clone, engineered cell enables increasing and the we and products by technology line fee, of unparalleled new complexity of functionality. engineered iPSC use an elements of of engineered the selection elements, a the established the on creation enabled uniquely one an top clonal engineered additional line, iPSC clonal incorporating This further cell to cell to functional demonstrated of engineering is that functional original master and is new that line multiplex additional multiplex both core iPSC of the of already
We new as approach candidates rapidly such are FTXXX product and efficiently candidates, as such innovate applying as well to as this to create product next-generation FTXXX.
FTXXX engineered preclinical of CAR cell enhance introduced line FTXXX target the we engineering master our line a targeting candidate BCMA, NK which multiple introduced BCMA candidate, fourth cell master ASGCT, track FTXXX. Built to expressed on application multiple of we fourth clonal We At line best-in-class remain surface at and stress the element, also quarter. proteins myeloma selectively is functional levels potential. targeting the tumors. product to a presented FTXXX, master already data Analogous multiple off-the-shelf to antigens Specifically the uniquely to on for create demonstrating for three on a expressed MICA established in in inducible element, off clonal FTXXX, at is engineered myeloma. for IND elements with new a our solid FTXXX, designed a cell CAR incorporates for ASGCT, further FTXXX functional engineered We targeted for submit many to cells FTXXX lymphoma, for a innate high FTXXX, fourth which for MICB, tumor-associated our product iPSC functional iPSC immunity. multi-antigen CAR are
To design region engage been The cells NK-cell cell-mediated stress stress post of shedding remain ligands targets While a domain, NK many tumor can our is a on common to receptor, the shown has escape, shedding. avoid mechanism novel αX ligands recognize of tumors specific uniquely on the by MICA/MICB, activating deployed cells. overcome NKGXD, to which escape tumor CAR and immunity. tumor
exciting a publication pan-tumor cell-mediated from solid cancers can In fact, believe and with that recent NK restore cytotoxic novel expression tumors domain-specific targeted three by of certain to with including the research effectively targeting for resistant cancer and a MHC to loss of immunology MICA/MICB We is antibodies investigators of Cancer in domain immunity. αX targeting especially T-cells. strategy, Dana-Farber I the be Institute demonstrated Class alpha
build including leveraging iPSC newly master cell our in also under with product Janssen's expertise with collaboration formed brings industry-leading our already unique ability our of iPSC engineered lines clonal deep using together oncology which our are Janssen, engineered cell established partners, increasing complexity, products We to multiplexed platform. domain and collaboration
CAR target, We with malignancy contributed have novel successfully for are launched building against collaboration this Janssen already strong antigen-binding solid one has we domains tumor momentum. hematologic proprietary and target constructs. one which
development step, clinical toward efficient these pathway initial an innovation, which In first research are including seek drive GMP to the processes iPSC a continue features As cell we accelerated the as collaboration's development constructs master scale functionalities commercial multiplex our to bring next-generation lines, best-in-class, the enable scaling NK to product we patients. for existing to off-the-shelf CAR-T and and of candidates. we of operations, incorporating into may cell support CAR for immunotherapies parallel, engineered and to and manufacturing and cancer
$X.X $XXX primarily financial XXXX million million same corporate to facility to the Pharmaceutical. associated and headquarters. ONO year. Revenue share-based for XXXX same million $X.X an compared for quarter million expenses $X.X second for legal for quarter increase convertible year. operating was cash current primarily ended share-based compensation, was an of fees. G&A into in $XX.X the The call Revenue same compensation expenses of expense Total stock Thank to five the you. our quarter preferred and quarter employee open-up headcount million. to new was stock $X.X XXXX the with XX.X to shares, million second outstanding compared to were compensation Turning to is for including convertible in compensation, conditions. shares in investments. expenses the of last which period any second of of increase G&A R&D our each net X.X quarter share-based I with for headcount was million expenses period the employee now attributable, increase increase last expenses lease stock attributable, and compared with the was including $X.X second company to was and our cash, outstanding the million, from were like the Common second development $XX.X quarter million our million, of the $XX.X derived and of results. in year. certain for XXXX the Research would XXXX expenses and shares last equivalents were of and non-cash The our compensation and common in under period Janssen collaboration for million of of in questions. The
